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Abstract
Objectives The aim of the study was to assess the
hemodynamic and metabolic actions of estrogen plus pro-
gestin therapy (EPT) in hypertensive, postmenopausal
women treated with perindopril (ACEI) or hydrochloro-
thiazide (HCTZ). A group of normotensive postmeno-
pausal women was also studied.
Methods 100 hypertensive and 40 normotensive post-
menopausal women were recruited for the study. The
hypertensive females were randomly assigned to receive
ACEI or HCTZ for 12 months. The patients of the ACEI
group and the patients of the HCTZ group, as well as
normotensives, were further subdivided into two subgroups
each. One subgroup received estrogen plus progestin
therapy (EPT?), the other subgroup received no hormone
replacement (EPT-). Combined hormone replacement
with transdermal patches releasing 17b-estradiol and nor-
ethisterone was used. Office and 24-hour ambulatory blood
pressure was measured at baseline and during follow-up.
Renal plasma flow (RPF) was measured using the clearance
of [125I]-iodohippuran. Pulse wave velocity (PWV) was
determined with an automatic device.
Results In normotensive postmenopausal women, trans-
dermal estrogen plus progestin therapy increases RPF and
insulin sensitivity, decreases PWV, decreases total and
LDL cholesterol, and decreases uric acid serum levels.
Perindopril (4 mg/day) and hydrochlorothiazide (25 mg/
day) were equally effective in reducing blood pressure in
postmenopausal, hypertensive subjects. In these females,
perindopril increased RPF and decreased PWV and plasma
insulin levels. These effects of the ACEI were not altered
by estrogen plus progestin therapy. Hydrochlorothiazide
decreased RPF and increased plasma insulin and uric acid
concentrations in hypertensive subjects whom were not
receiving estrogen plus progestin therapy.
Conclusions The unfavorable metabolic and hemody-
namic actions of the diuretic were counteracted by estrogen
plus progestin therapy. Concomitant estrogen plus pro-
gestin therapy may be a method to avoid unfavorable
hemodynamic and metabolic effects of thiazide diuretics in
hypertensive, postmenopausal women.
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Introduction
Despite the high prevalence of hypertension in middle-
aged women, less than half of the patients receive adequate
treatment, especially in older age groups when the risk of
morbidity and mortality is the highest, due to coronary
heart disease [1].
The reason for rising blood pressure levels at menopause
is multifactorial and not completely understood. There are
several hypotheses that include the role of sex hormones,
the renin–angiotensin system, weight gain, and sympa-
thetic activation [2].
Klungel et al. [3] observed an increased use of diuretics
among women treated for high blood pressure than men
(56.3 vs. 49.4 %). These results are similar to those pub-
lished in the HOT study, in which more women than men
received diuretic at the time of inclusion (36.4 vs. 29.8 %)
[4]. The reason for the preferential use of diuretics in the
treatment of hypertension in postmenopausal women is
pathophysiological considerations, such as the increase of
intravascular volume associated with sodium retention. The
improvement of sodium sensitivity by thiazide diuretics
causes the desired natriuretic effect. Additional benefit of
their use is positive impact on calcium metabolism, which
in the postmenopausal period is impaired. The Framingham
study demonstrated much lower incidence of femoral
fractures in women who were treated long-term with thi-
azide diuretics currently or in the past ([2 years) [5].
The use of thiazide diuretics, however, is associated
with an increased serum uric acid. Therefore, as it is an
independent factor of cardiovascular complications, this
parameter and the unfavorable impact on lipid and carbo-
hydrate metabolism may be considered as the cause of less
benefits of treatment in a comparable age group of women
and men.
Estrogen deficit in postmenopausal women seems to be
the causative agent of severe vasoconstriction due to
overexpression of the angiotensin AT1 receptor [6]. Plasma
renin activity increases after menopause and the upregu-
lation of angiotensin AT2 receptors and downregulation of
angiotensin AT1 receptors at this time might influence
response to therapy [7]. Therefore, for treatment of
hypertension in postmenopausal women the most desirable
medication would be such that could reverse or at least
slow the disadvantages associated with vascular remodel-
ing. The theory increased sensitivity of AT1 receptors to
angiotensin II is considered to be one of the mechanisms of
hypertension in postmenopausal women. Thus, the use of
drugs that block the renin-angiotensin-aldosterone system
fits perfectly in the pathogenesis of postmenopausal
hypertension and the benefits of their use are presented in
the clinical trials [8].
The newest statement on estrogen plus progestin ther-
apy by the European and International Menopause soci-
eties reaffirms that this therapy is the most effective
treatment for vasomotor symptoms and other symptoms
of the menopause [9]. Overall, it is suggested that treat-
ment with hormone therapy should be individualized.
There is no standard approach to estrogen progestin
therapy (EPT) decision-making. It depends on the severity
of menopausal symptoms, impairment of quality of life,
women’s personal risk-factor status, concomitant diseases,
her personal preferences, and also before the age of
60 years and within 10 years after menopause when
overall benefits are more likely to outweigh risks.
These points and pathophysiological aspects of hyper-
tension after menopause captured an interest of the
simultaneous influence of antihypertensive treatment and
hormone substitution on hemodynamic and metabolic
parameters. Renal blood flow is impaired in many post-
menopausal women with hypertension [10]. It is conceiv-
able that ACEI counteracts this impairment, whereas
diuretics have no influence on it. The effects of EPT on
hemodynamic and metabolic actions of ACEI and diuretics
are unknown thus far. Therefore, a study was designed to
assess the hemodynamic and metabolic actions of hormone
replacement in hypertensive postmenopausal women trea-
ted with an ACEI or a diuretic. To assess the influence of
EPT in subjects receiving no antihypertensive drugs, a
group of normotensive postmenopausal women was also
studied.
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Methods
Women with recently diagnosed, untreated essential
hypertension in grade 1 or 2 according to ESH/ESC 2007
Guidelines [11] in the menopause were recruited to the
study. They were qualified by a general practitioner or
gynecologist as postmenopausal women aged 49–53,
white. All women screened in the study reported full
cessation of the menses for at least 12 months. The final
menstrual period (FMP) is determined retrospectively.
Among the surveyed women it was above 1 year. In
determining this criterion, we used STRAW guidelines
(stages of reproductive aging workshop) system [12]. The
authors claim: twelve months of amenorrhea is consid-
ered to represent clinical menopause and is termed
‘‘postmenopause’’. All the women had the expected
postmenopausal rise of follicle-stimulating hormone lev-
els (FSH 78.32 ± 8.73 IU/mL) and experienced flushes
or other menopausal vasomotor symptoms. Therefore,
according to the randomization, they were advised to
undergo EPT and antihypertensive therapy. Women
without hypertension but only with vasomotor symptoms
were randomized for EPT or nothing. The exclusion
criteria were: a first-degree relative having breast cancer,
hyperplasia in endometrial biopsy, prior thromboembolic
diseases, current or previous use of estrogen plus pro-
gestin therapy or contraceptives, diabetes, kidney failure,
thyroid disease, and heart and other chronic diseases. All
the screened women had a negative mammography in the
12 months prior to the study.
In the invitation letter, hypertensive women were asked to
participate in a study on hypertension treatment and meno-
pausal symptoms or menopausal symptoms only in women
without hypertension. Participants gave their informed
consent before the study. The study was conducted in
accordance with The Declaration of Helsinki and was
approved by the Ethics Committee of the University of
Medical Sciences in Poznan. All women underwent a
physical examination and biochemical screening at baseline.
The screening included 140 women with menopausal
vasomotor symptoms, who met the inclusion but not
exclusion criteria, and who had not yet been treated for
hypertension. At two separate visits a week apart (wash-out
period), hypertension was confirmed as the mean value of
three office measurements C140/90 mmHg and \180/
110 mmHg. Women with secondary hypertension or elec-
trolyte disturbances (serum potassium levels) were exclu-
ded. Recruited women had no contraindications to
transdermal estrogen plus progestin therapy or antihyper-
tensive treatment. The control group consisted of 40
women with normal blood pressure (\140/90 mmHg two
separate visits) measured in comparable conditions, who
were also offered transdermal estrogen plus progestin
therapy because of menopausal vasomotor symptoms.
Hypertensive women were then randomized at the
beginning of the study (using sealed envelopes) to two
therapeutic groups: with diuretic–hydrochlorothiazide
25 mg/day po (n = 50) or with ACEI– perindopril 4 mg/
day po (n = 50) and to a group receiving estrogen plus
progestin therapy (EPT?) and a group not treated with
hormones (EPT-). Normotensive women were random-
ized only to EPT? or EPT- groups. Estrogen plus pro-
gestin therapy consisted of transdermal patches releasing
17b-estradiol (0.05 mg/24 h) and norethisterone (0.25 mg/
24 h) named Estracomb TTS.
All participants had control measurements performed
after 6 months and 1 year. At the end, 20 women did not
complete the study (4 due to side effect of perindopril–
cough, 6 needed additional hypotensive therapy, 2 on
ACEI and 4 on HCTZ and 10 for no reason). All women
completed the study in the normotensive group.
Finally, groups of 20 hypertensive women in each
therapeutic option and 20 normotensive women, with and
without EPT, were taken for statistical calculations in the
order in which they have completed the 12-month follow-
up period in the study.
Measurements
Systolic (SBP) and diastolic (DBP) office blood pressure
levels were measured after 5 min in sitting position, using a
validated automatic device (Omron 705 CP) placed on the
arm with the higher blood pressure level. Each time, the
average of three readings was used. Ambulatory blood
pressure measurements were performed in all patients at
entrance into the study, as well as after 6 and 12 months
using an automatic device (MOBIL-O-GRAPH). The
devices were programmed to record the blood pressure
during a 24 h period at the intervals of 30 min during
daytime and intervals of 60 min at night.
Pulse wave velocity (PWV) was determined with an
automatic device (Complior, Colson AS, Paris, France) by
recording common carotid artery, as well as femoral artery
pressure wave forms using a pressure-sensitive transducer
(TY 306 Fukuda Denshi Co, Tokyo, Japan). Measurements
were repeated during 20 cardiac cycles and the mean value
was calculated. Details concerning the validation and the
reproducibility of this method have been described [13]. In
our laboratory, the variation coefficient was \6 %.
Renal plasma flow (RPF) was measured as the clearance
of 125I-iodohippuran using a constant infusion technique
with timed urine sampling [14, 15]. Plasma levels of glucose
and insulin, as well as serum concentrations of total cho-
lesterol and low-density cholesterol, were determined using
40 Clin Res Cardiol (2015) 104:38–50
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fasting blood samples. Serum creatinine concentration was
measured by use of the Jaffe´ reaction. Glomerular filtration
rate (GFR) was estimated by the Cockroft-Gault equation for
females.
Statistical analysis
Student’s t test was used for comparisons continuous
variables and normality of distribution of an analyzed
feature in both populations. t test with the Cochran–Cox
adjustment was used when variances of analyzed variables
in both populations were different or Wilcoxon–Mann–
Whitney test when there was no normal distribution.
Baseline characteristics were compared by use of
ANOVA (for parametric variables) or the Kruskal–Wallis
test (for non-parametric variables), respectively, followed
by comparisons of the different groups in pairs. Means
were compared using the Kruskal–Wallis test one-way
analysis of ranks, followed by comparisons of groups of
interest in pairs. If groups were significantly different,
multiple comparison Dunn test was used.
Multiple linear regression models were calculated for
selected parameters of the influence of HCTZ and EPT
(hypertensive females). Also, models with interactions
were calculated. If the regression coefficients b for the
interactions of independent variables were significant,
these models were used to interpret the variability of the
dependent variable. F test verifies the statistical signifi-
cance of all variables in the model. Similar multiple linear
regression models were also calculated to indicate the
hypertension and EPT influence.
Values represent mean ± standard deviation (SD)
unless stated otherwise. A p value \0.05 was considered
statistically significant.
Results
Data at entry into the study show that the different sub-
groups of hypertensive patients were well matched
(Table 1). The same is true for the two subgroups of nor-
motensive women. As compared with the normotensive
women, hypertensive women had higher office and
ambulatory blood pressure levels, higher plasma insulin
and uric acid levels a higher PWV, as well as a smaller
nocturnal fall of systolic and diastolic blood pressure (Fall
SBP24 Fall SBP24), lower GFR and RPF (Table 1). Lipid
profile did not differ significantly between the subgroups.
The lipid profile was also statistically equal between nor-
motensive as well as hypertensive women. There were no
differences at baseline in checked parameters between the
ACEI and HCTZ groups (not shown in the Table).
The influence of estrogen plus progestin therapy
on hemodynamic and metabolic measures
in hypertensive postmenopausal women
Both perindopril and hydrochlorothiazide caused a similar
decrease of blood pressure in hypertensive females
(Table 2). After 6-(data not shown) and 12-month treat-
ment, there were statistically significant differences
between the EPT? and EPT- subgroups in systolic and
diastolic office blood pressure levels in ACEI treatment
group. We did not observe such influence of EPT on
ABPM (mSBP24 and mDBP24) among all treated women
(Table 3). Multiple linear regression models have shown,
after 12 months of hypotensive treatment, there were no
significant differences in the nocturnal blood pressure fall
(Fall SBP24 and Fall DBP24) by EPT treatment, despite its
significant change in comparison to baseline values for
ACEI and HCTZ subgroups. However, there was statisti-
cally significant lowering effect of the EPT on total and
LDL cholesterol, as well as insulin levels in all hyperten-
sive women (Table 4).
During the study, the plasma glucose concentrations did
not change in hypertensive patients treated with perindopril
or hydrochlorothiazide (Table 3). Plasma insulin levels
decreased significantly in the patients treated with perin-
dopril, both in those subjects treated with and those without
hormone replacement. At the end of the study, plasma
insulin levels in the two subgroups treated with the ACEI
(EPT? vs. EPT-) did not differ significantly. In the
hypertensive females treated with hydrochlorothiazide,
plasma insulin level decreased significantly compared to
baseline values only in the subgroup receiving estrogen
plus progestin therapy to a level of 16.4 lU/mL at study
end (Table 3). In contrast, plasma insulin and uric acid
concentrations arose in those without estrogen plus pro-
gestin therapy (HCTZ; EPT- group) to 23.8 lU/mL and
7.5 mg/dL, respectively. The difference of plasma insulin
and uric acid levels, between the two HCTZ subgroups
(EPT? vs. EPT-) was statistically significant (p \ 0.01
and p \ 0.001, respectively) at the end of the study.
At the end of the study, PWV of the perindopril group
decreased significantly from baseline to similar levels both
in patients with and in those without estrogen plus pro-
gestin therapy (Table 3). In the HCTZ group, PWV
decreased significantly in the patients receiving estrogen
plus progestin therapy. However, after 12-month treatment
PWV was still higher in these patients than in females of
the perindopril group receiving hormone replacement (9.3
vs. 8.8 m/s, p \ 0.01—p value not shown in the table). In
contrast to all other subgroups, PWV increased in patients
without EPT during treatment with hydrochlorothiazide. At
the end of the study, PWV was 11.5 m/s in these patients as
Clin Res Cardiol (2015) 104:38–50 41
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compared with 9.3 m/s in patients of the HCTZ EPT?
group (p \ 0.01) (Table 3).
Glomerular filtration rate (GFR) remained unchanged in
all subgroups during the study (Table 3). RPF increased
significantly compared to baseline values in the patients
treated with perindopril, both in those with and those
without estrogen plus progestin therapy (Table 3). At the
end of the study, RPF in the two subgroups did not differ
between ACEI (EPT? vs. EPT-) groups. RPF also
increased in the patients treated with hydrochlorothiazide
and received EPT. However, RPF was substantially
decreased in the patients of the hydrochlorothiazide
Table 1 Baseline characteristics of the examined groups
Hypertensives Normotensives
ACEI HCTZ EPT? EPT- p
EPT? EPT- p EPT? EPT- p
BP measurements
mSBP (mmHg) 161.2 ± 9.6* 162.2 ± 9.8* NS 159.7 ± 7.6* 160.4 ± 9.0* NS 136.2 ± 2.5 136.5 ± 3.0 NS
mDBP (mmHg) 97.8 ± 2.4* 98.9 ± 3.1* NS 97.1 ± 2.7* 98.4 ± 3.5* NS 85.0 ± 2.6 85.6 ± 2.6 NS
mSBP24 (mmHg) 149.2 ± 6.3* 148.1 ± 6.9* NS 149.0 ± 6.1* 148.5 ± 7.0* NS 129.4 ± 2.7 129.9 ± 2.6 NS
mDBP24 (mmHg) 92.5 ± 1.5* 92.8 ± 1.9* NS 92.7 ± 1.6* 92.9 ± 1.6* NS 82.9 ± 2.3 83.6 ± 2.3 NS
Fall SBP24 (%) 7.0 ± 2.6* 7.1 ± 3.1* NS 7.0 ± 2.2* 7.8 ± 3.2* NS 9.9 ± 1.9 9.9 ± 1.9 NS





5.9 ± 0.4 6.0 ± 0.4 NS 5.8 ± 0.5 6.0 ± 0.4 NS 5.9 ± 0.5 5.8 ± 0.4 NS
LDL cholesterol
(mmol/L)
3.7 ± 0.5 3.9 ± 0.4 NS 3.7 ± 0.5 3.9 ± 0.4 NS 3.8 ± 0.5 3.7 ± 0.4 NS
HDL cholesterol
(mmol/L)
1.4 ± 0.1 1.4 ± 0.1 NS 1.4 ± 0.1 1.4 ± 0.1 NS 1.4 ± 0.1 1.3 ± 0.1 NS
Triglycerides (mmol/L) 1.7 ± 0.1 1.7 ± 0.1 NS 1.7 ± 0.1 1.7 ± 0.2 NS 1.6 ± 0.2 1.7 ± 0.1 NS
Glucose (mmol/L) 5.3 ± 0.6 5.5 ± 0.6 NS 5.2 ± 0.6 5.5 ± 0.6 NS 5.4 ± 0.6 5.3 ± 0.6 NS
Insulin (lI/L) 19.1 ± 6.4* 19.7 ± 7.3* NS 19.6 ± 4.8* 20.3 ± 7.8* NS 16.4 ± 5.1 17.0 ± 6.4 NS
Uric acid (mg/dL) 6.2 ± 2.1* 6.2 ± 2.0* NS 6.2 ± 1.6* 6.4 ± 2.1* NS 5.0 ± 1.4 5.0 ± 1.2 NS
Hemodynamic parameters
PWV (m/s) 10.7 ± 1.7* 10.8 ± 1.4* NS 10.8 ± 1.6* 10.8 ± 2.1* NS 8.9 ± 1.5 8.6 ± 1.1 NS
RPF (mL/min) 421.9 ± 81.1* 423.7 ± 74.2* NS 426.3 ± 66.0* 423.0 ± 75.1* NS 488.7 ± 47.3 496.6 ± 45.0 NS
GFR (mL/min) 105.9 ± 7.5* 104.7 ± 7.7* NS 106.9 ± 5.8* 105.2 ± 5.7* NS 115.1 ± 5.2 114.8 ± 5.9 NS
mSBP/mDBP mean systolic/diastolic blood pressure in office measurement, mSBP24/mDBP24 mean systolic/diastolic blood pressure in
24-hambulatory monitoring, Fall SBP24/Fall DBP24 day-night fall of systolic/diastolic blood pressure in 24-hour ambulatory monitoring
* p \ 0.05–0.0001 values that are, at baseline, significantly different in comparison to hypertensives ACEI (EPT?; EPT-) and HCTZ (EPT?;
EPT-) vs. normotensives (EPT?; EPT), respectively
Table 2 The comparison of the change in systolic and diastolic blood pressure in ABPM between ACEI group and HCTZ group after 12 months
of hypotensive treatment (both groups without EPT) showing no significant difference in lowering blood pressure by both drugs
DSBP24 (mmHg) DDBP24 (mmHg)
Mean Day Night Mean Day Night
ACEI 21.1 ± 8.1 20.0 ± 7.8 25.0 ± 9.1 10.0 ± 2.7 7.0 ± 2.9 15.3 ± 6.0
HCTZ 21.9 ± 7.1 20.9 ± 7.5 26.4 ± 9.2 9.8 ± 2.6 7.9 ± 2.8 16.6 ± 3.8
p value NS NS NS NS NS NS
DSBP24;DDBP24 difference in mean systolic; diastolic blood pressure in 24-hour ambulatory monitoring after 12 months in comparison to
baseline













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Clin Res Cardiol (2015) 104:38–50 43
123
subgroup without EPT. At the end of the study, RPF in the
HCTZ group was 474.4 mL/min in EPT? comparing with
336.2 mL/min in EPT- (p \ 0.001). In both hypertensive
subgroups treated with EPT, the changes of PWV and of
RPF were inversely correlated (r = -0.67, p \ 0.01 in the
patients of the perindopril group treated with EPT; r = -
0.43, p \ 0.05 in the patients of the HCTZ group who
received EPT).
The effects of estrogen plus progestin therapy
on hemodynamic and metabolic measures
in normotensive postmenopausal women
In comparison to baseline values, office systolic and dia-
stolic blood pressure levels decreased in the normotensive
females treated with hormone replacement. The same was
concluded for the systolic ambulatory blood pressure.
EPT? and EPT- groups differed significantly in office BP
as well as nocturnal fall of BP (respectively, p \ 0.0001
and 0.001). Such a change was not observed in ABPM
(mSBP24 and mDBP24). Moreover the influence of EPT on
BP changes (DSBP24 and DDBP24) turned out to be
insignificant (Table 3).
At the end of the study, there were statistically signifi-
cant differences between the EPT? and EPT- subgroups
in total and LDL cholesterol levels (p \ 0.001 and
p \ 0.01, respectively). These values were significantly
changed from baseline only in EPT subgroups.
Plasma glucose levels remained unchanged during the
study in normotensive women with EPT as well as in
women without EPT (Table 3). However, plasma insulin
and uric acid concentrations decreased in the estrogen plus
progestin therapy, whereas these measurements remained
unaltered in the subgroup without EPT. At the end of the
study, plasma insulin concentration was 12.7 lU/mL in the
EPT? subgroup as compared with 16.6 lU/mL in the
EPT- subgroup (p \ 0.01). Uric acid levels were also
significantly lower by EPT (p \ 0,001).
During the study, PWV decreased in normotensive
females given estrogen plus progestin therapy, whereas
Table 4 Multiple linear
regression models of the
influence of 12-month EPT and
HCTZ (in comparison to ACEI)
and their interaction in
hypertensive women (n = 80)
b The regression coefficient and
its error of estimation (SEb)
* Statistically significant value
EPT Hypotensive treatment (HCTZ) HCTZ and EPT
Glucose b = -0.11 (0.13) b = 0.16 (0.13)
p = 0.37502 p = 0.21538
mSBP b = -0.50 (0.62) b = 0.35 (0.62)
p = 0.42252 p = 0.57408
mDBP b = 1.28 (0.41) b = 0.58 (0.41)
p = 0.00243* p = 0.16132
Fall SBP24 b = 0.69 (0.44) b = -2.05 (0.44)
p = 0.1187 p = 0.00001*
Fall DBP24 b = 0.30 (0.39) b = -1.72 (0.39)
p = 0.44003 p = 0.00003*
PWV b = -0.25 (0.56) b = 2.49 (0.56) b = -1.97 (0.80)
p = 0.656 p = 0.00003* p = 0.01579*
GFR b = -0.45 (1.26) b = -1.20 (1.26)
p = 0.72251 p = 0.34487
RPF b = 30.70(17.74) b = -152.55(17.74) b = 107.50 (25.09)
p = 0.08764 p = \0.000001* p = 0.00005*
Insulin b = -4.91 (1.35) b = 4.51 (1.35)
p = 0.00048* p = 0.00125*
Total cholesterol b = -0.32 (0.11) b = 0.36 (0.11)
p = 0.00683* p = 0.0022*
LDL b = -0.30 (0.12) b = 0.38 (0.12)
p = 0.01194* p = 0.00212*
HDL b = 0.004 (0.02) b = -0.02 (0.02)
p = 0.85202 p = 0.28727
Triglycerides b = -0.11 (0.13) b = 0.16 (0.13)
p = 0.37502 p = 0.21538
Uric acid b = -0.55 (0.52) b = 2.21 (0.52) b = -1.56 (0.73)
p = 0.286821 p = 0.000051* p = 0.03526*
44 Clin Res Cardiol (2015) 104:38–50
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PWV remained unaltered in women without EPT
(Table 3). After 12 months, PWV was 7.8 m/s in EPT?
and 8.8 m/s in EPT-. The difference was statistically
significant (p \ 0.05). GFR remained unchanged during
the study in both subgroups (Table 3). In contrast, RPF
increased in EPT? and remained unchanged in EPT- in
comparison to baseline values. At the end of the study, RPF
was 538.8 mL/min in EPT? and 485 mL/min in EPT-
(p \ 0.0001).
In multivariate analysis, we revealed significant interac-
tions between estrogen plus progestin therapy and the type of
hypotensive treatment in metabolic and hemodynamic
parameters such as insulin changes (insulin delta is not
shown in the table) (Fig. 1) and uric acid plasma concen-
trations (Fig. 2; Table 4) and as well as PWV and RPF
(Table 4; Figs. 3, 4). Moreover levels of insulin, total cho-
lesterol, LDL cholesterol, and uric acid were significantly
lower in all women treated with EPT (Table 5; Fig. 5).
Discussion
Menopause is associated with enhanced progression of
atherosclerosis [16]. The stiffness of the female aortic wall
increases more rapidly during the menopausal years than
the changes at the same time of life in men [17].
Our study addresses the EPT timing hypothesis that the
beneficial vascular effects of EPT after menopause will
only accrue if such therapy is given before advanced ath-
erosclerosis develops [18–20].
In the WHI study, the average age of randomized
women was 67 years, whereas our population was much
younger and thus free of the complications of meno-
pause. We believe that this is the best time (shortly after
menopausal transition) to demonstrate the impact of


























Fig. 1 The interaction between the type of hypotensive treatment and
EPT on insulin change (unfilled triangles) shows its reduction by an
average of 4.87 lI/L in women with EPT added to HCTZ (b the
regression coefficient and its error of estimation, EPT estrogen plus




























Fig. 2 The interaction between the type of hypotensive treatment and
EPT on uric acid plasma level shows its reduction by an average of
1.56 mg/dL in patients with EPT added to HCTZ (b the regression
coefficient and its error of estimation, EPT estrogen plus progestin


























Fig. 3 The interaction between the type of hypotensive treatment and
EPT on PWV shows its reduction by an average of 1.97 m/s in
patients with EPT added to HCTZ (b the regression coefficient and its
error of estimation, PWV pulse wave velocity, EPT estrogen plus
progestin therapy, ACEI angiotensin converting enzyme inhibitor,
HCTZ hydrochlorothiazide)
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antihypertensive treatment to reverse negative aspects of
menopause on the cardiovascular and metabolic status
[21, 22].
The study shows that estrogen plus progestin therapy
has several favorable effects in normotensive postmeno-
pausal women. Office blood pressure fell slightly,
nocturnal fall of SBP increased significantly reaching the
standard values ([10 %), and PWV decreased, while
RPF increased. The fall of PWV is partially caused by
the decrease of blood pressure and restoring the noctur-
nal fall of BP, but also because of other reasons. The
concomitant increase of RPF, however, suggests that
structural changes in the vessel walls may contribute.
This assumption is supported by the findings of Hayward
et al. [23].
The improvement of elastic properties of the aorta may
result from increase of vasa vasorum flow which contribute
substantially to the nutrition of the outer layers of the
thoracic aorta and therefore modulate the structure of the
aortic wall [24, 25].
During EPT in normotensives plasma insulin levels
were decreased, while plasma glucose concentrations
remained unchanged, indicating enhanced insulin sensi-
tivity. Renal parameters together with metabolic profile
improvement (decrease of total cholesterol, its LDL frac-
tion and uric acid) were caused by beneficial influence of
EPT introduced in women early after menopausal transi-
tion (aged 49–53 years).
With the doses used in our study, the perindopril and the
hydrochlorothiazide had similar antihypertensive effects on
blood pressure in ABPM in hypertensive women. There-
fore, we suspect that a complex mechanism played a role in
improving hemodynamic parameters after application of
transdermal EPT.
Performing blood pressure measurements (office and
ABPM) allowed us to demonstrate the usefulness of ABPM
in effect on circadian profile and also revealed that dif-
ferences in the office measurements turned out to be
insignificant in ABPM. In contrast, improvement in noc-
turnal blood pressure fall in the ‘‘net’’ dimension after
application of EPT and antihypertensive treatment
becomes favorable in the aspect of reduction of cardio-
vascular events.
Among women with hypertension, nocturnal pressure
fall of systolic and diastolic blood pressure increased sig-
nificantly and was restored ([10 %) in the group treated
with ACEI. Diuretic treatment did not restore the nocturnal
pressure fall, but the addition of hormone substitution
increased significantly both systolic and diastolic falls. The
absence of nocturnal blood pressure fall is recognized in
the literature as a factor correlating with increased risk of
cardiovascular complications [26–28]. In postmenopausal
women the percentage of ‘‘non-dippers’’ is higher, at
around 40 % compared with men [29]. Some authors have
expressed the view that women ‘‘non-dippers’’ are more
likely to develop cardiovascular complications of hyper-
tension than men [30, 31]. Lack of improvement of the
night fall in the group treated with HCTZ may be due to






















Fig. 4 The interaction between the type of hypotensive treatment and
EPT on RPF shows its increase by an average of 107.5 mL/min in
patients with EPT added to HCTZ (b the regression coefficient and its
error of estimation, RPF renal plasma flow, EPT estrogen plus
progestin therapy, ACEI angiotensin converting enzyme inhibitor,
HCTZ hydrochlorothiazide
Table 5 Multiple linear regression models of the influence of
hypertension and 12-month EPT on metabolic profile in all examined
women (n = 120)
Hypertension EPT
Glucose b = -0.03 (-0.02) b = -0.09 (-0.08)
p = 0.796689 p = 0.375755
Insulin b = 3.18 (0.24) b = -4.55 (-0.36)
p = 0.005481* p = 0.000037*
Total cholesterol b = 0.03 (0.02) b = -0.34 (-0.34)
p = 0.7821 p = 0.000159*
LDL b = 0.04 (0.03) b = -0.34 (-0.32)
p = 0.687098 p = 0.000301*
HDL b = -0.01 (-0.06) b = 0.004 (0.02)
p = 0.540434 p = 0.789504
Triglycerides b = -0.003 (-0.01) b = -0.01 (-0.05)
p = 0.903618 p = 0.564273
Uric acid b = 1.23 (0.31) b = -1.34 (0.29)
p = 0.000115* p = 0.000011*
b the regression coefficient and its error of estimation (SEb)
* Statistically significant value
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profile, which can only be assessed by monitoring the
pressure all day.
Messerli et al. [32] found in their meta-analysis that
HCTZ lowers BP well during daytime when patients are
seen in the physician’s office, but has less effect during the
night and early morning hours. So it appeared useful to
make ABPM measurements that documented the daily
pressure profile improvement on EPT in women treated
with HCTZ. This is because this diuretic is still often used
as a first-line drug in the treatment of hypertension in
postmenopausal women, not only because of the patho-
mechanism of hypertension in this period (the retention of
sodium in the body), but also because of the desired ben-
eficial effect on the calcium metabolism.
Angiotensin converting enzyme inhibitor, in addition to
its antihypertensive action had several other favorable
effects in hypertensive postmenopausal females [33]. The
drug decreased PWV, not only because of the fall of blood
pressure but also because of other than hypotensive effects.
RPF was increased and plasma insulin levels were
decreased in the patients without hormone replacement
during treatment with the ACEI. Estrogen plus progestin
therapy did not significantly alter PWV, RPF, and plasma
insulin concentrations in these women. In contrast to the
ACEI, HCTZ had some unfavorable effects in hypertensive
postmenopausal women who received no estrogen plus
progestin therapy. PWV did not change in spite of a
significant fall of blood pressure. RPF was decreased and
plasma insulin levels rose. Unfavorable influence of factors
on the elastic properties of vessel walls and their remod-
eling changes with age and female hormone loss during
menopausal transition, and it may predominate on hypo-
tensive effect of HCTZ on hemodynamic parameters which
finally causes their deterioration. Estrogen plus progestin
therapy counteracts these effects.
There are conflicting reports concerning the influence of
estrogens on plasma insulin levels in normotensive females
[34, 35]. In our study, estrogen plus progestin therapy
decreased plasma insulin concentrations in normotensive
postmenopausal women and antagonised the thiazide-
induced rise of plasma insulin in hypertensive females.
High insulin levels cause proliferation of vascular smooth
muscle cells [36, 37] and increase calcium influx into these
cells [38] resulting in increased vascular media thickness
and vascular stiffness [39]. This could be the cause of
unchanged PWV in spite of decreased blood pressure values
as well as of the decrease of RPF in our patients treated with
HCTZ and receiving no estrogen plus progestin therapy.
In a meta-analysis including 103,268 men and 87,349
women, antihypertensive therapy provided similar pro-
tection against cardiovascular events in both sexes. Fur-
thermore, in this meta-analysis, there was no evidence that
ACEI was superior to diuretics in preventing cardiovas-




















Fig. 5 The comparison of
plasma levels of insulin, total
cholesterol, LDL cholesterol,
uric acid between women
treated with (n = 60) or without
EPT (n = 60) (EPT estrogen
plus progestin therapy)
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should, however, keep in mind that for the trials included
in the meta-analysis both pre- and postmenopausal women
were recruited. In our study with postmenopausal women
receiving no estrogen plus progestin therapy, the ACEI
perindopril—in addition to its antihypertensive action—
decreased plasma insulin concentrations and increased
RPF. The diuretic HCTZ had the opposite effects. The
unfavorable actions of HCTZ on plasma insulin levels and
RPF were counteracted by estrogen plus progestin ther-
apy. In contrast, EPT did not significantly influence RPF
and plasma insulin concentrations in patients treated with
perindopril. The multivariate analysis showed that the
positive cumulative effect of EPT and HCTZ seems to be
an attractive concept for the abolition of both the adverse
effects of the thiazide diuretic on metabolic and hemo-
dynamic parameters, and concomitant treatment of men-
opausal symptoms. The benefits may even surpass
antihypertensive therapy with ACE inhibitors and EPT.
This transdermal combination in the present study has
been found to have positive effects on lipid metabolism.
The difference in total and LDL cholesterol levels
between groups (lower levels in EPT group with ACEI
and in normotensives and not changed in HCTZ group)
after 12 months may partially explain the beneficial
effects of estrogen plus progestin therapy on arterial
compliance and stay in line with impact on cardiovascular
endpoints.
Transdermal application of low doses of 17b-estradiol
and norethisterone was used as estrogen plus progestin
therapy in our study. This provides sustained release and
more constant blood levels of the drugs than those that
could be obtained with oral application. Furthermore, the
transdermal application avoids a first pass effect and,
therefore, interactions with agents affecting drug meta-
bolising enzymes in the liver [41].
Conclusions
In conclusion, our study shows that transdermal estrogen
plus progestin therapy increases RPF and insulin sensitivity
as well as decreases PWV, total and LDL cholesterol, uric
acid serum levels in normotensive postmenopausal women.
Perindopril (4 mg/day) and hydrochlorothiazide (25 mg/
day) were equally effective in reducing blood pressure in
hypertensive postmenopausal females. In these patients,
perindopril increased RPF and decreased PWV and plasma
insulin levels. These effects of the ACEI were not altered
by estrogen plus progestin therapy. HCTZ decreased RPF
and increased plasma insulin and uric acid concentrations
in hypertensive, postmenopausal women not receiving
estrogen plus progestin therapy. These unfavorable actions
of the diuretic were counteracted by estrogen plus
progestin therapy. Concomitant estrogen plus progestin
therapy may be a method to avoid unfavorable hemody-
namic and metabolic effects of thiazide diuretics in
hypertensive postmenopausal women.
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